Heart Failure With Preserved Ejection Fraction and Lower Natriuretic Peptide: Clinical Characteristics and Change in Natriuretic Peptide Levels.

ABSTRACT:

Background

Recent heart failure (HF) guidelines emphasize the importance of recognizing patients with mild elevations in NT-proBNP (N-terminal pro-B-type natriuretic peptide). While NT-proBNP is a key biomarker for diagnosing HF and predicting outcomes, its levels are often lower than expected in HF with preserved ejection fraction.

Methods

Using data from the SUPPORT (Supplemental Benefit of an Angiotensin Receptor Blocker in Hypertensive Patients With Stable Heart Failure Using Olmesartan) trial, we examined the temporal changes in NT-proBNP and long-term outcomes in patients with HF with preserved ejection fraction (left ventricular ejection fraction ≥50%) categorized by NT-proBNP levels (≤55, 55-125, 125-300, and ≥300 pg/mL).

Results

Among 602 patients with HF wit

SUBMITTER: Teramoto K 

PROVIDER: S-EPMC12684791 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature